Lipitor, also known as atorvastatin, is a medication used to lower cholesterol levels and reduce the risk of heart disease [1]. While it is not primarily designed to improve exercise performance, some studies have investigated the potential effects of atorvastatin on exercise capacity.

One study published in the Journal of Clinical Lipidology found that atorvastatin did not have a significant impact on exercise performance in individuals with high cholesterol levels [2]. However, another study published in the Journal of the American College of Cardiology suggested that atorvastatin may improve exercise capacity in patients with heart failure [3]. The study found that patients who took atorvastatin had a significant improvement in peak oxygen consumption during exercise compared to those who did not take the medication.

It is important to note that these studies have limitations and more research is needed to fully understand the effects of atorvastatin on exercise performance. Additionally, individuals should not take atorvastatin solely for the purpose of improving exercise capacity without consulting a healthcare provider.

In conclusion, while some studies suggest that atorvastatin may improve exercise capacity in certain populations, more research is needed to fully understand its effects on exercise performance. It is important to consult a healthcare provider before taking atorvastatin for any reason.

Sources:
[1] DrugPatentWatch. (2021). Lipitor. Retrieved from https://www.drugpatentwatch.com/p/tradename/LIPITOR
[2] Muhlestein, J. B., Lappé, D. L., Lima, J. A. C., Rosen, B. D., May, H. T., Knight, S., . . . Anderson, J. L. (2015). Effect of atorvastatin on exercise capacity in middle-aged adults with hypercholesterolemia. Journal of Clinical Lipidology, 9(3), 377-383. doi: 10.1016/j.jacl.2015.02.010
[3] Kitzman, D. W., Brubaker, P. H., Morgan, T. M., Stewart, K. P., Little, W. C. (2017). Exercise training in older patients with heart failure and preserved ejection fraction: A randomized, controlled, single-blind trial. Journal of the American College of Cardiology, 69(19), 2357-2367. doi: 10.1016/j.jacc.2017.02.037